Concurrent chemoradiotherapy combined with nimotuzumab in stage III–IVa nasopharyngeal carcinoma: a retrospective analysis

• Published in: Journal of cancer research and clinical oncology Vol. 149; no. 6; pp. 2327 - 2344
• Main Authors: Cai, Zhuochen, Chen, Dongni, Qiu, Wenze, Liang, Chixiong, Huang, Yingying, Zhou, Jiayu, Zhan, Zejiang, Xiang, Yanqun, Guo, Xiang, Lv, Xing
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2023; Springer Nature B.V
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer Research; carcinoma; Chemoradiotherapy; Chemoradiotherapy - adverse effects; Chemotherapy; clinical trials; Hematology; Humans; Immunotherapy; Induction Chemotherapy; Internal Medicine; Medical prognosis; Medicine; Medicine & Public Health; Metastases; Monoclonal antibodies; Nasopharyngeal carcinoma; Nasopharyngeal Carcinoma - drug therapy; Nasopharyngeal Neoplasms - drug therapy; nomogram; Nomograms; Oncology; Original Article – Clinical Oncology; Original – Clinical Oncology; Patients; prognosis; Prospective Studies; Radiation therapy; regression analysis; Retrospective Studies; Survival; Targeted cancer therapy; therapeutics; Throat cancer; Toxicity; Nasopharyngeal carcinoma; Survival; Concurrent chemoradiotherapy; Nimotuzumab; Prediction model

Purpose The efficacy and safety of nimotuzumab (NTZ) added to concurrent chemoradiotherapy (CCRT) were investigated in patients with stage III–IVa nasopharyngeal carcinoma (NPC). Methods Patients with stage III–IVa NPC treated with CCRT, with or without NTZ, were screened between January 2015 and De...